Develops drugs for various diseases, including cancer and autoimmune diseases.
Jun 2026Revenue $259M/yrExpenses $412M/yr
No trendCash runway ≈ 3.2 years from Jun 2026
Figures by year
When will Schrodinger be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $259M and expenses $412M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $256M | $423M | −$167M |
| Dec 2024 | $208M | $417M | −$209M |
| Dec 2023 | $217M | $394M | −$177M |
| Dec 2022 | $181M | $328M | −$147M |
| Dec 2021 | $138M | $249M | −$111M |
| Dec 2020 | $108M | $169M | −$60.9M |
| Dec 2019 | $85.5M | $124M | −$38.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.